Bg pattern

ONDANSETRON BLUEFISH 4 mg ORALLY DISINTEGRATING TABLETS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use ONDANSETRON BLUEFISH 4 mg ORALLY DISINTEGRATING TABLETS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

PACKAGE LEAFLET: INFORMATION FOR THE USER

Ondansetron Bluefish 4 mg orodispersible tablets EFG

ondansetron

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

Contents of the pack and other information

  1. What Ondansetron Bluefish orodispersible tablets are and what they are used for
  2. What you need to know before you take Ondansetron Bluefish orodispersible tablets
  3. How to take Ondansetron Bluefish orodispersible tablets
  4. Possible side effects
  5. Storage of Ondansetron Bluefish orodispersible tablets
  6. Pack contents and further information

1. What Ondansetron Bluefish orodispersible tablets are and what they are used for

Ondansetron Bluefish orodispersible tablets are a fast-dissolving tablet when placed on the tongue.

This medicine contains ondansetron, which belongs to a group of medicines called antiemetics that can be used to prevent nausea and vomiting.

Ondansetron orodispersible tablets can be used for:

  • Stopping the effects of nausea and vomiting caused by cytotoxic chemotherapy in children and adults
  • Preventing post-operative nausea and vomiting in children and adults
  • Stopping the effects of nausea and vomiting caused by radiotherapy in adults

If you are not sure why you have been prescribed this treatment, ask your doctor.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you take Ondansetron Bluefish orodispersible tablets

Do not take Ondansetron Bluefish orodispersible tablets

  • if you are allergic to ondansetron or any of the other ingredients of this medicine (listed in section 6).
  • if you are taking apomorphine (used for the treatment of Parkinson's disease)

Warnings and precautions

Tell your doctor, pharmacist, or nurse before you start taking Ondansetron Bluefish orodispersible tablets:

  • if you are pregnant or might become pregnant soon,
  • if you are breast-feeding
  • if you have liver problems
  • if you have bowel obstruction or severe constipation
  • if it is for children under 2 years or with a body surface area of less than 0.6 m2.

Other medicines and Ondansetron Bluefish orodispersible tablets

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, such as phenytoin, carbamazepine, rifampicin, tramadol.

Pregnancy and breast-feeding

Ondansetron Bluefish orodispersible tablets should not be used during the first trimester of pregnancy. This is because Ondansetron Bluefish orodispersible tablets may slightly increase the risk of a baby being born with a cleft lip and/or cleft palate (openings or gaps in the upper lip or in the roof of the mouth). If you are already pregnant, think you might be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using Ondansetron Bluefish orodispersible tablets. If you are a woman of childbearing age, you are advised to use an effective method of contraception.

Ondansetron may pass into breast milk. Therefore, it is recommended that breast-feeding mothers should not breast-feed their babies if they are taking Ondansetron Bluefish orodispersible tablets.

Driving and using machines

Ondansetron Bluefish orodispersible tablets do not affect the ability to drive or use machines.

Ondansetron Bluefish orodispersible tablets contain aspartame, glucose, maltodextrin, sorbitol, sulphur dioxide, and sodium

Ondansetron Bluefish orodispersible tablets contain aspartame (E 951). This medicine contains 0.88 mg of aspartame in each 4 mg orodispersible tablet.

Aspartame is a source of phenylalanine, which may be harmful for people with phenylketonuria (a rare genetic disorder in which phenylalanine accumulates because the body is unable to eliminate it properly).

Ondansetron Bluefish orodispersible tablets contain sorbitol (E 420). This medicine contains 8.4 mg of sorbitol in each 4 mg orodispersible tablet.

Ondansetron Bluefish orodispersible tablets contain glucose and maltodextrin. If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.

It may cause cavities.

Ondansetron Bluefish orodispersible tablets contain sulphur dioxide (E 220). This medicine may cause severe allergic reactions and bronchospasm (sudden feeling of suffocation) because it contains "sulphur dioxide".

Ondansetron Bluefish orodispersible tablets contain sodium. This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is, essentially "sodium-free".

3. How to take Ondansetron Bluefish orodispersible tablets

Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.

After starting treatment

Ondansetron orodispersible tablets start to work within 1-2 hours. If you vomit within 1 hour of taking the tablet, take another dose. Otherwise, do not take more tablets or reduce the time between doses. Consult your doctor if the discomfort persists.

Treatment and prevention of nausea and vomiting associated with chemotherapy and/or radiotherapy

Adults

The recommended dose is 8 mg, 1 to 2 hours before chemotherapy, followed by 8 mg every 12 hours for 5 days. Your doctor will decide if you should be given an injection instead of tablets.

Elderly

The same dose as for adults.

Children over 2 years and adolescents under 18 years:

The dose is individual and depends on the child's body size/surface area. Ondansetron Bluefish should not be used in children with a total body surface area of less than 0.6 m2.

Children from 6 months and adolescents

  • The recommended dose is up to 4 mg twice a day
  • It can be administered for 5 days

Prevention of post-operative nausea and vomiting

Adults

The usual dose is 16 mg before anesthesia or, alternatively, 8 mg one hour before anesthesia followed by additional doses of 8 mg at 8 and 16 hours. Your doctor will decide if you should be given an injection instead of tablets.

Elderly

There is limited experience in the use of ondansetron in the elderly. Ondansetron is well tolerated by patients over 65 years with chemotherapy (see previous section).

Patient with moderate or severe hepatic impairment:the total daily dose should not exceed 8 mg.

Patient with poor sparteine/debrisoquine metabolism:no alteration of dose or dosing frequency is needed.

Do not remove the tablets from the blister pack until you are ready to take the medicine.

The tablets should be taken as follows:

Do not remove Ondansetron Bluefish orodispersible tablets from the blister pack until you are ready to take the medicine.

To prevent the tablet from breaking, it is important not to press the tablet until the blister pack is opened (Figure A).

The tablets in each blister pack are separated by perforations. Separate each tablet by following the perforations (Figure 1). The coating film should be removed with care. Starting from the corner marked with the arrow (Figure 2 and 3).

The tablets should be removed with dry hands and placed on the tongue (Figure 4). The tablet will disintegrate, after which it can be swallowed with water.

Figure A. Figure 1.

Broken blister pack with diagonal lines indicating do not reuse or contamination hazardSix square adhesive dressings with a central oval visible arranged in two rows and three columns

Figure 2. Figure 3.

Scheme of a shaded triangular area within an oval shape with arrows indicating direction and movementHands holding a needle with two open wings showing the direction of insertion with double arrows

Figure 4.

Hand holding a capsule or tablet with thumb and index finger preparing to ingest it

If you take more Ondansetron Bluefish orodispersible tablets than you should

If you or your child take more Ondansetron Bluefish than you should, talk to a doctor or go to the nearest hospital immediately. Take the medicine with you. You can also call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.

If you forget to take Ondansetron Bluefish orodispersible tablets

Do not take a double dose to make up for forgotten doses.

If you forget a dose and feel nauseous or vomit, take an Ondansetron Bluefish tablet as soon as possible and then continue with the treatment as indicated. If you forget a dose but do not feel nauseous or vomit, take the next dose as indicated.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Some people may be allergic to the medicine, in case any of the following symptoms appear soon after taking Ondansetron, stop taking the medicine and inform your doctor immediately.

  • Sudden appearance of "pips" and pain or oppression in the chest.
  • Swelling of eyelids, face, lips, mouth, or tongue.
  • Rash on the skin or hives anywhere on the body.
  • Collapse

Other possible side effects:

Very common (may affect more than 1 in 10 people)

  • Headache

Common (may affect up to 1 in 10 people)

  • Constipation
  • Feeling of warmth or flushing

Uncommon (may affect up to 1 in 100 people)

  • Arrhythmias, chest pain with or without ST segment depression, palpitations (irregular heartbeat) or slow heartbeat
  • Asymptomatic increase in liver function test results
  • Seizures, involuntary body movements including extrapyramidal reactions such as dystonic reactions, including upward rolling movements of the eyes and dyskinesia have been observed without clinically significant consequences
  • Hiccup
  • Low blood pressure (hypotension)

Rare (may affect up to 1 in 1,000 people)

  • Immediate allergic reaction, which can be severe, such as swelling of the mouth and throat that causes difficulty breathing
  • There have also been cases of dizziness when ondansetron is administered intravenously, which in most cases is prevented or resolved with an increase in the infusion period
  • Vision problems (e.g., blurred vision) associated with ondansetron by injection

Very rare (may affect up to 1 in 10,000 people)

  • Temporary loss of vision almost always by injection

Most cases of blindness have resolved within 20 minutes. Most patients had received chemotherapeutic agents, including cisplatin. Some of the cases of transient blindness reported were of cortical origin.

The strawberry flavor contains sulphur dioxide (E220) which may cause rare hypersensitivity reactions and bronchospasm.

Frequency not known (cannot be estimated from the available data)

Myocardial ischemia

The signs include:

  • sudden chest pain or
  • chest oppression

If you think any of the side effects you are experiencing are serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Vigilance System for Human Use: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Ondansetron Bluefish orodispersible tablets

Keep this medicine out of the sight and reach of children.

Store in the original package to protect from light.

Store below 30°C.

Do not use this medicine after the expiry date which is stated on the carton and blister after "EXP.". The expiry date is the last day of the month shown.

Do not use this medicine if you notice visible signs of deterioration, such as discoloration or broken tablets.

Medicines should not be disposed of via wastewater or household waste. Return the containers and any unused medicines to your usual pharmacy for disposal. This will help protect the environment.

6. Pack contents and further information

Composition of Ondansetron Bluefish orodispersible tablets

The active substance is ondansetron. Each orodispersible tablet contains 4 mg of ondansetron.

The other excipients are: aspartame (E951), crospovidone type B, magnesium stearate (E572), microcrystalline cellulose (E460), Pharmaburst TM C1, (which contains mannitol (E421), sorbitol (E420), crospovidone (type A) and colloidal silicon dioxide), strawberry flavor, (which contains glucose, maltodextrin, gum arabic (E414) 2.3% and sulphur dioxide (E220)), stearic acid fumarate and sodium.

Appearance of the product and pack contents

Orodispersible tablet.

White, flat, round, and beveled orodispersible tablet.

Ondansetron Bluefish orodispersible tablets are available in packs of: 6, 10, 14, 20, 30, 50, 60, 100 orodispersible tablets in aluminum/OPA/PVC blisters.

Not all pack sizes may be marketed.

Marketing authorization holder and manufacturer

Marketing authorization holder:

Bluefish Pharmaceuticals AB

P.O. Box 49013,

100 28 Stockholm,

Sweden

Manufacturer:

Bluefish Pharmaceuticals AB,

Gävlegatan 22,

113 30 Stockholm,

Sweden

Sofarimex Industria Química e Farmacêutica S.A.

Av. das Indústrias- Alto do Colaride, Cacem, 2735-213

Portugal

You can request more information about this medicine by contacting the local representative of the marketing authorization holder:

Bluefish Pharma S.L.U.,

AP 36007

2832094 Madrid, Sucursal 36

This leaflet is available for the blind or for those with visual impairments upon request.

This medicine is authorized in the Member States of the European Economic Area under the following names

State

Medicine name

Germany

Ondansetron Bluefish 4mg schmelztabletten

Denmark

Ondansetron Bluefish 4mg smeltetabletter

Spain

Ondansetron Bluefish 4mg comprimidos bucodispersibles EFG

Norway

Ondansetron Bluefish 4mg smeltetabletter

Poland

Ondansetron Bluefish

United Kingdom

(Northern Ireland)

Ondansetron 4mg orodispersible tablets

Sweden

Ondansetron Bluefish 4mg munsönderfallande tabletter

Date of last revision of this leaflet: June 2022

Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

Online doctors for ONDANSETRON BLUEFISH 4 mg ORALLY DISINTEGRATING TABLETS

Discuss questions about ONDANSETRON BLUEFISH 4 mg ORALLY DISINTEGRATING TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (37)
Doctor

Dmytro Horobets

Family medicine 7 years exp.

Dr. Dmytro Horobets is a licensed family medicine physician in Poland, specialising in endocrinology, diabetology, obesity management, gastroenterology, pediatrics, general surgery, and pain medicine. He offers online consultations for adults and children, providing personalised medical support for a wide range of acute and chronic health concerns.

Areas of expertise:

  • Endocrinology: diabetes type 1 and type 2, prediabetes, thyroid disorders, metabolic syndrome, hormonal imbalance.
  • Obesity medicine: structured weight management plans, nutritional counselling, obesity-related health risks.
  • Gastroenterology: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), liver and biliary conditions.
  • Pediatric care: infections, respiratory symptoms, digestive issues, growth and development monitoring.
  • General surgery support: pre- and post-surgical consultations, wound care, rehabilitation.
  • Pain management: chronic and acute pain, back pain, joint pain, post-traumatic pain syndromes.
  • Cardiovascular health: hypertension, cholesterol control, risk assessment for heart disease.
  • Preventive medicine: regular check-ups, health screenings, long-term management of chronic conditions.

Dr. Horobets combines evidence-based medicine with a patient-centred approach. He carefully evaluates each patient’s medical history and symptoms, offering clear explanations and structured treatment plans adapted to individual needs.

Whether you need help managing diabetes, tackling weight-related health issues, interpreting lab results, or receiving general family medicine support, Dr. Horobets provides professional online care tailored to your specific health goals.

Camera Book a video appointment
€60
5.0 (5)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques. For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance. Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults. In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions. Patients commonly seek his care for: 

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns

Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.

Camera Book a video appointment
€80
5.0 (181)
Doctor

Yevgen Yakovenko

General surgery 12 years exp.

Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain and Germany. He specialises in general, paediatric, and oncological surgery, internal medicine, and pain management. He offers online consultations for adults and children, combining surgical precision with therapeutic support. Dr Yakovenko works with patients across different countries and provides care in Ukrainian, Russian, English, and Spanish.

Areas of medical expertise:

  • Acute and chronic pain: headaches, muscle and joint pain, back pain, abdominal pain, postoperative pain. Identifying the cause, selecting treatment, and creating a care plan.
  • Internal medicine: heart, lungs, gastrointestinal tract, urinary system. Management of chronic conditions, symptom control, second opinions.
  • Pre- and postoperative care: risk assessment, decision-making support, follow-up after surgery, rehabilitation strategies.
  • General and paediatric surgery: hernias, appendicitis, congenital conditions, both planned and urgent surgeries.
  • Injuries and trauma: bruises, fractures, sprains, soft tissue damage, wound care, dressing, referral when in-person care is required.
  • Oncological surgery: diagnosis review, treatment planning, and long-term follow-up.
  • Obesity treatment and weight management: a medical approach to weight loss, including assessment of underlying causes, evaluation of comorbidities, development of a personalised plan (nutrition, physical activity, pharmacotherapy if needed), and ongoing progress monitoring.
  • Imaging interpretation: analysis of ultrasound, CT, MRI, and X-ray results, surgical planning based on imaging data.
  • Second opinions and medical navigation: clarifying diagnoses, reviewing current treatment plans, helping patients choose the best course of action.

Experience and qualifications:

  • 12+ years of clinical experience in university hospitals in Germany and Spain.
  • International education: Ukraine – Germany – Spain.
  • Member of the German Society of Surgeons (BDC).
  • Certified in radiological diagnostics and robotic surgery.
  • Active participant in international medical conferences and research.

Dr Yakovenko explains complex topics in a clear, accessible way. He works collaboratively with patients to analyse health issues and make evidence-based decisions. His approach is grounded in clinical excellence, scientific accuracy, and respect for each individual.

If you are unsure about a diagnosis, preparing for surgery, or want to discuss your test results – Dr Yakovenko will help you evaluate your options and move forward with confidence.

Camera Book a video appointment
€50
0.0 (0)
Doctor

Joao Silva

General medicine 6 years exp.

Dr. João Silva is a physician with training and experience in the field of General and Family Medicine, dedicated to providing healthcare focused on the well-being and quality of life of his patients. Throughout his professional career, he has developed broad clinical competencies, striving to maintain a medical practice based on scientific evidence and continuous knowledge updates.

Between 2013 and 2019, he completed the Integrated Master's Degree in Medicine at the Abel Salazar Institute of Biomedical Sciences in Porto, where he acquired a solid academic and clinical education.

Subsequently, between January 2021 and December 2021, he completed the General Internship at the Entre Douro e Vouga Hospital Center in Santa Maria da Feira, where he had the opportunity to work in different hospital settings and deepen his competencies in several areas of medicine.

From January 2022 until March 2026, he works as a Resident Physician in General and Family Medicine at USF Salvador Machado in Oliveira de Azeméis, developing clinical activities in primary healthcare, follow-up of chronic patients, and health promotion in the community.

Complementing his medical training, Dr. João Silva also completed a Postgraduate Degree in Continuing and Palliative Care at CESPU, strengthening his preparation in the comprehensive approach to patient care, especially in situations requiring prolonged care and multidisciplinary support.

Camera Book a video appointment
€55

Frequently Asked Questions

Is a prescription required for ONDANSETRON BLUEFISH 4 mg ORALLY DISINTEGRATING TABLETS?
ONDANSETRON BLUEFISH 4 mg ORALLY DISINTEGRATING TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in ONDANSETRON BLUEFISH 4 mg ORALLY DISINTEGRATING TABLETS?
The active ingredient in ONDANSETRON BLUEFISH 4 mg ORALLY DISINTEGRATING TABLETS is ondansetron. This information helps identify medicines with the same composition but different brand names.
Who manufactures ONDANSETRON BLUEFISH 4 mg ORALLY DISINTEGRATING TABLETS?
ONDANSETRON BLUEFISH 4 mg ORALLY DISINTEGRATING TABLETS is manufactured by Bluefish Pharmaceuticals Ab (Publ). Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of ONDANSETRON BLUEFISH 4 mg ORALLY DISINTEGRATING TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether ONDANSETRON BLUEFISH 4 mg ORALLY DISINTEGRATING TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to ONDANSETRON BLUEFISH 4 mg ORALLY DISINTEGRATING TABLETS?
Other medicines with the same active substance (ondansetron) include ONDANSETRON ACCORD 2 mg/ml INJECTABLE SOLUTION, ONDANSETRON ARISTO 4 mg ORALLY DISINTEGRATING TABLETS, ONDANSETRON ARISTO 8 mg ORALLY DISINTEGRATING TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media